1-4 of 4
Eric Wattel, MDPhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Results of a Phase II Study of Guadecitabine (SGI-110) in Higher Risk MDS, CMML or Low Blast Count AML Patients Refractory to or Relapsing after Azacitidine (AZA) Treatment

Marie Sebert, MD, Cecile Bally, Pierre Peterlin, MD, Odile Beyne-Rauzy, MD PhD, Laurence Legros, MDPhD, marie Pierre Gourin, MD PhD, Laurence Sanhes, MD, Eric Wattel, MDPhD, Emmanuel Gyan, MD PhD, Sophie Park, MD PhD, Aspasia Stamatoullas, MD, Anne Banos, Kamel Laribi, Simone Jueliger, PhD, Luke Bevan, Cendrine Chaffaut, Rosa Sapena, Benedicte Samey, Fatiha Chermat, Sylvie Chevret, Lionel Ades, MD PhD, Pierre Fenaux, MD PhD
Journal: Blood
Blood (2016) 128 (22): 347.
https://doi.org/10.1182/blood.V128.22.347.347
Published: 2016
Journal Articles

Outcome of Lower Risk Non Del 5q MDS after Failure of Erythropoiesis Stimulating Agents (ESA), and Impact of Post-ESA Treatment on Survival: A Retrospective European Study

Sophie Park, MD PhD, Jean-François Hamel, Andrea Toma, Charikleia Kelaidi, MD, Maria Campelo Diez, Valeria Santini, MD, Enrico Balleari, MD, Jennifer Schemenau, Rosa Sapena, Katharina Goetze, MD, Catharina Mueller-Thomas, MD, Odile Beyne-Rauzy, MD PhD, Aspasia Stamatoullas, MD, Ioannis Kotsianidis, Agnes Guerci, MD, Dominique Bordessoule, Pascale Cony-Makhoul, MD, Stéphane Cheze, MD PhD, Eric Wattel, MDPhD, Christian Rose, Norbert Vey, Ulrich Germing, MD, Guillermo Sanz, MD PhD, François Dreyfus, MD, Pierre Fenaux, MD PhD
Journal: Blood
Blood (2015) 126 (23): 1665.
https://doi.org/10.1182/blood.V126.23.1665.1665
Published: 2015
Journal Articles

A Phase II Add-on Study of Vorinostat (VOR) in Higher Risk Myelodysplastic Syndrome with Failure of Hypomethylating Agents (HMA): The GFM Azavor Study

Thomas Prebet, MD, Jacques Delaunay, MD, Eric Wattel, MDPhD, Thorsten Braun, MD PhD, Pascale Cony-Makhoul, MD, Sophie Dimicoli, MD, Stefan Wickenhauser, MD, Julie Lejeune, Sylvie Chevret, Fatiha Chermat, Pierre Fenaux, MD PhD, Norbert Vey
Journal: Blood
Blood (2015) 126 (23): 2900.
https://doi.org/10.1182/blood.V126.23.2900.2900
Published: 2015
Journal Articles

Decreased Expression of Anti-DNMT1 Tumor-Suppressor microRNAs in Azacitidine (AZA)-Resistant Cells Independently Predicts Survival in Patients Treated with AZA for Higher Risk Myelodysplastic Syndrome (HRMDS) and Oligoblastic Acute Myeloid Leukemia (AML)

Francoise Solly, MD, Catherine Koering, PhD, Aminetou mint Mohamed, PhD, Delphine Maucort-Boulch, MD, Guillaume Robert, PhD, Patrick Auberger, PhD, Pascale Flandrin-Gresta, MDPhD, Lionel Adès, MD PhD, Pierre Fenaux, MD PhD, Olivier Kosmider, MD PhD, Emmanuelle Tavernier-Tardy, MDPhD, Jérôme Cornillon, MD, Denis Guyotat, MDPhD, Lydia Campos, MD PhD, Franck Mortreux, PhD, Eric Wattel, MDPhD
Journal: Blood
Blood (2015) 126 (23): 2840.
https://doi.org/10.1182/blood.V126.23.2840.2840
Published: 2015